Successful Immunochemotherapy for Burkitt Lymphoma During Pregnancy as a Bridge to Postpartum High-Dose Methotrexate Therapy: A Case Report and Review of the Literature

Stang, Axel; Schwärzler, P.; Schmidtke, Susanne; Kobbe, Robin

doi:10.1016/j.clml.2019.12.012

Cited by 5 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunotherapy is rarely administered during pregnancy because of concerns about the potential effects on the fetus. For ICIs, seven cases of women becoming pregnant while undergoing ICI treatment have been reported ( 76 – 81 ), and four cases of ICI therapy beginning during pregnancy, with or without chemotherapy ( 76 , 82 – 84 ). Three of the melanoma mothers showed disease progression after delivery ( 80 , 82 , 83 ), and one had an emergency Caesarean section at 24 weeks gestation due to tumor progression and died the day after surgery ( 82 ).…”

Section: Fluctuations: Health States Regulate Idmentioning

confidence: 99%

Immunodiagnosis — the promise of personalized immunotherapy

Wang,

Xiong,

Wang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Immunotherapy showed remarkable efficacy in several cancer types. However, the majority of patients do not benefit from immunotherapy. Evaluating tumor heterogeneity and immune status before treatment is key to identifying patients that are more likely to respond to immunotherapy. Demographic characteristics (such as sex, age, and race), immune status, and specific biomarkers all contribute to response to immunotherapy. A comprehensive immunodiagnostic model integrating all these three dimensions by artificial intelligence would provide valuable information for predicting treatment response. Here, we coined the term “immunodiagnosis” to describe the blueprint of the immunodiagnostic model. We illustrated the features that should be included in immunodiagnostic model and the strategy of constructing the immunodiagnostic model. Lastly, we discussed the incorporation of this immunodiagnosis model in clinical practice in hopes of improving the prognosis of tumor immunotherapy.

show abstract

Section: Fluctuations: Health States Regulate Idmentioning

confidence: 99%

Immunodiagnosis — the promise of personalized immunotherapy

Wang,

Xiong,

Wang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Corticosteroid therapy can successfully treat most ir AEs, but a combination of immunosuppressors is needed to combat more serious adverse reactions [10,11]. Immunosuppressant methotrexate were used to treat rheumatic ir AEs [11], and high-dose methotrexate can be applied to immunochemotherapy in many type of cancers [12,13]. However, since it is unclear whether a patient can undergo immunosuppressive therapy of these immunosuppressors safely, there is an urgent need to find some biomarkers to predict the drug sensitivity of immunosuppressants.…”

Section: Introductionmentioning

confidence: 99%

Construction of an immune-related lncRNA signature pair for predicting oncologic outcomes and the sensitivity of immunosuppressor in treatment of lung adenocarcinoma

Zhuang

Chen

et al. 2022

Respir Res

View full text Add to dashboard Cite

Background Although immunotherapy has shown clinical activity in lung adenocarcinoma (LUAD), LUAD prognosis has been a perplexing problem. We aimed to construct an immune-related lncRNA pairs (IRLPs) score for LUAD and identify what immunosuppressor are appropriate for which group of people with LUAD. Methods Based on The Cancer Genome Atlas (TCGA)-LUAD cohort, IRLPs were identified to construct an IRLPs scoring system by Cox regression and validated in the Gene Expression Omnibus (GEO) dataset using log-rank test and the receiver operating characteristic curve (ROC). Next, we used spearman’s correlation analysis, t-test, signaling pathways analysis and gene mutation analysis to explore immune and molecular characteristics in different IRLP subgroups. The “pRRophetic” package was used to predict the sensitivity of immunosuppressant. Results The IRLPs score was constructed based on eight IRLPs calculated as 2.12 × (MIR31HG|RRN3P2) + 0.43 × (NKX2-1-AS1|AC083949.1) + 1.79 × (TMPO-AS1|LPP-AS2) + 1.60 × (TMPO-AS1|MGC32805) + 1.79 × (TMPO-AS1|PINK1-AS) + 0.65 × (SH3BP5-AS1|LINC01137) + 0.51 × (LINC01004|SH3PXD2A-AS1) + 0.62 × (LINC00339|AGAP2-AS1). Patients with a lower IRLPs risk score had a better overall survival (OS) (Log-rank test PTCGA train dataset < 0.001, PTCGA test dataset = 0.017, PGEO dataset = 0.027) and similar results were observed in the AUCs of TCGA dataset and GEO dataset (AUC TCGA train dataset = 0.777, AUC TCGA test dataset = 0.685, AUC TCGA total dataset = 0.733, AUC GEO dataset = 0.680). Immune score (Cor = -0.18893, P < 0.001), stoma score (Cor = -0.24804, P < 0.001), and microenvironment score (Cor = -0.22338, P < 0.001) were significantly decreased in the patients with the higher IRLP risk score. The gene set enrichment analysis found that high-risk group enriched in molecular changes in DNA and chromosomes signaling pathways, and in this group the tumor mutation burden (TMB) was higher than in the low-risk group (P = 0.0015). Immunosuppressor methotrexate sensitivity was higher in the high-risk group (P = 0.0052), whereas parthenolide (P < 0.001) and rapamycin (P = 0.013) sensitivity were lower in the high-risk group. Conclusions Our study established an IRLPs scoring system as a biomarker to help in the prognosis, the identification of molecular and immune characteristics, and the patient-tailored selection of the most suitable immunosuppressor for LUAD therapy.

show abstract

Antineoplastics

2021

Reactions Weekly

View full text Add to dashboard Cite

Successful Immunochemotherapy for Burkitt Lymphoma During Pregnancy as a Bridge to Postpartum High-Dose Methotrexate Therapy: A Case Report and Review of the Literature

Cited by 5 publications

References 38 publications

Immunodiagnosis — the promise of personalized immunotherapy

Immunodiagnosis — the promise of personalized immunotherapy

Construction of an immune-related lncRNA signature pair for predicting oncologic outcomes and the sensitivity of immunosuppressor in treatment of lung adenocarcinoma

Antineoplastics

Contact Info

Product

Resources

About